Yesterday, Sept. 15, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $35.04 to $4,142,629.75.

Highlighted Stocks Traded by Insiders:

Realpage (RP) - FREE Research Report

Chaney William P, who is EVP Enterprise Solutions at Realpage, sold 4,125 shares at $17.83 on Sept. 15, 2015. Following this transaction, the EVP Enterprise Solutions owned 113,206 shares meaning that the stake was reduced by 3.52% with the 4,125-share transaction.

The shares most recently traded at $18.29, up $0.46, or 2.52% since the insider transaction. Historical insider transactions for Realpage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 754
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 10,754
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 79,732

The average volume for Realpage has been 222,900 shares per day over the past 30 days. Realpage has a market cap of $1.4 billion and is part of the technology sector and computer software & services industry. Shares are down 16.53% year-to-date as of the close of trading on Tuesday.

RealPage, Inc. provides demand software and software-enabled services for the rental housing and vacation rental industries in the United States. Currently, there are 2 analysts who rate Realpage a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings rates Realpage as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Realpage Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Layne Christensen (LAYN) - FREE Research Report

Obus Nelson, who is Director at Layne Christensen, bought 70,000 shares at $6.18 on Sept. 15, 2015. Following this transaction, the Director owned 253,802 shares meaning that the stake was boosted by 38.08% with the 70,000-share transaction.

Caliel Michael J, who is President and CEO at Layne Christensen, bought 7,500 shares at $6.09 on Sept. 15, 2015. Following this transaction, the President and CEO owned 12,500 shares meaning that the stake was boosted by 150% with the 7,500-share transaction.

The shares most recently traded at $6.39, up $0.30, or 4.71% since the insider transaction. Historical insider transactions for Layne Christensen go as follows:

  • 4-Week # shares bought: 5,685
  • 12-Week # shares bought: 115,000
  • 24-Week # shares bought: 128,474

The average volume for Layne Christensen has been 275,500 shares per day over the past 30 days. Layne Christensen has a market cap of $120.5 million and is part of the industrial goods sector and materials & construction industry. Shares are down 38.05% year-to-date as of the close of trading on Tuesday.

Layne Christensen Company provides water management, construction, and drilling services in North America and internationally. Currently, there are no analysts who rate Layne Christensen a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LAYN - FREE

TheStreet Quant Ratings rates Layne Christensen as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Layne Christensen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte (INCY) - FREE Research Report

Levy Richard S, who is EVP, Chief Drug Dev Officer at Incyte, sold 4,301 shares at $130.00 on Sept. 15, 2015. Following this transaction, the EVP, Chief Drug Dev Officer owned 16,926 shares meaning that the stake was reduced by 20.26% with the 4,301-share transaction.

The shares most recently traded at $129.34, down $0.66, or 0.51% since the insider transaction. Historical insider transactions for Incyte go as follows:

  • 4-Week # shares sold: 7,150
  • 12-Week # shares sold: 7,150
  • 24-Week # shares sold: 22,181

The average volume for Incyte has been 1.2 million shares per day over the past 30 days. Incyte has a market cap of $23.1 billion and is part of the health care sector and drugs industry. Shares are up 79.82% year-to-date as of the close of trading on Tuesday.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. The company has a P/E ratio of 1424.6. Currently, there are 11 analysts who rate Incyte a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INCY - FREE

TheStreet Quant Ratings rates Incyte as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including poor profit margins and generally higher debt management risk. Get the full Incyte Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.